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Abstract 
Background: In precision medicine biomarkers stratify patients into groups that are offered different treatments, 
but this may conflict with the principle of equal treatment. While some patient characteristics are seen as relevant for 
unequal treatment and others not, it is known that they all may influence treatment decisions. How biomarkers influ-
ence these decisions is not known, nor is their ethical relevance well discussed.
Methods: We distributed an email survey designed to elicit treatment preferences from Norwegian doctors work-
ing with cancer patients. In a forced-choice conjoint analysis pairs of hypothetical patients were presented, and we 
calculated the average marginal component effect of seven individual patient characteristics, to estimate how each of 
them influence doctors’ priority-setting decisions.
Results: A positive biomarker status increased the probability of being allocated the new drug, while older age, 
severe comorbidity and reduced physical function reduced the probability. Importantly, sex, education level and 
smoking status had no significant influence on the decision.
Conclusion: Biomarker status is perceived as relevant for priority setting decisions, alongside more well-known 
patient characteristics like age, physical function and comorbidity. Based on our results, we discuss a framework that 
can help clarify whether biomarker status should be seen as an ethically acceptable factor for providing unequal treat-
ment to patients with the same disease.
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Background
Stratification of patient groups into smaller subgroups or 
single patients is a hallmark of precision medicine, but 
may be perceived as discriminatory against other patients 
in the same group. Such practice may challenge common 
sense morality and the principle of formal equality, which 
requires equal treatment to patients that are equal in all 
ethically relevant aspects [1, 2]. Traditionally, potential to 
benefit, risk and severity of disease are considered rele-
vant, while gender, ethnicity and religion are not. Among 
contested factors are patient age and personal responsi-
bility for health [2, 3]. Despite disagreement over some of 
these factors’ relevance, it is known that all may influence 
clinical decision making and treatment allocation [4–6]. 
Is and should biomarker status be considered a relevant 
reason for unequal treatment concerning patients with 
the same disease?
The development of precision medicine has brought 
great promises [7] and by tailoring diagnostics and treat-
ment to individual patients, the overarching motto of 
precision medicine can be achieved: “The right drug to 
the right patient at the right time” [8]. This belief is espe-
cially developed in oncology, where an increasing number 
of new targeted therapies are given only to a small selec-
tion of patients based on biomarkers  [9]: examples are 
mutations that lead to upregulation of epidermal growth 
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factor receptor (EGFR) in lung cancers [10], expression 
of erb-b2 receptor tyrosine kinase 2 (ERBB2, also known 
as HER2) in breast cancer [11], B-Raf proto-oncogene 
(BRAF) mutations in melanoma [12], and expression of 
the CD274 molecule known as Programmed death-ligand 
1 (PD-L1) expression in various cancer types [13, 14].
Biomarkers have the potential to promote better and 
fairer decision making [15, 16] but also lead to a range 
of ethical and social considerations [17]. Discrete Choice 
Experiments (DCEs) for cancer treatment have mostly 
been studied among patients [18], but studies among 
doctors are also prevalent [19–21]. It is of special interest 
to study how doctors perceive the relevance of biomarker 
status, as they are responsible for treatment decisions. To 
our knowledge, no prior study that examined treatment 
preferences among doctors has included biomarkers and 
a priority setting scenario. Accordingly, we set out to 
investigate Norwegian cancer doctors’ preferences when 
making hypothetical priority setting decisions based on 
individual patient characteristics. We were particularly 
interested in how biomarker status was perceived in rela-




The growing costs of cancer care is a global problem [22, 
23], and this is further complicated by the fact that many 
new cancer drugs offer only modest benefits [24]. This is 
also true for Norway. In 2016 the Norwegian Parliament 
unanimously endorsed a set of priority setting criteria for 
use in the health sector: health benefit and resource use 
(estimated as cost-effectiveness) and severity of disease 
(estimated as loss of quality adjusted life years (QALYs) 
without treatment) [25, 26]. Based on clinical trial data 
submitted by the drug manufacturers, a national system, 
the New Methods System, evaluates new drugs for reim-
bursement in the health care system using group level 
estimates of the three criteria [27]. The Norwegian Direc-
torate of Health, together with the relevant professional 
associations, implement the newly approved drugs into 
national clinical guidelines. Clinicians must then, within 
these guidelines, make use of group level data combined 
with clinical discretion in their clinical decisions for indi-
vidual patients.
Our aim was to explore this tension between group-
level evidence and decisions based on individual patient 
characteristics by means of an email survey among Nor-
wegian cancer doctors. In the experiment, pairs of hypo-
thetical patients were presented to our respondents, with 
the information that a new cancer drug could be given 
to only one of the two (see supplementary material for 
survey questionnaire). The two patients were equal at a 
group level, with similar severity of disease and a cost-
effectiveness of the new treatment so high that it would 
only just be approved for reimbursement. Their individ-
ual characteristics, like age and comorbidity, varied. We 
then asked the respondents, based on the information 
provided, to allocate one of the patients the new drug.
Experimental design
We designed a conjoint analysis (CA), a DCE constructed 
to elicit stated preferences. Compared to revealed pref-
erences, which are derived from real world observations, 
stated preferences are what respondents declare when 
asked hypothetical questions. The strengths of using 
stated preferences compared to revealed preferences are 
well-known [28]: standardised data collection makes it 
easier to estimate statistical relationships between patient 
characteristics and treatment decisions. It is easier to 
explore decisions involving biomarkers, as they are not 
yet established in clinical practice. Also, hypothetical sce-
narios may elicit better answers from respondents, espe-
cially concerning potentially sensitive issues like clinical 
priority setting. Still, we acknowledge that no hypotheti-
cal design can fully simulate real patients and clinical 
decisions. What respondents say that they would do may 
not be what they actually would do in real life decision 
making.
First developed for marketing research and cosumer 
preferences [29, 30], different types of CA have later been 
used in health care research [31, 32]. In this particular 
study, we use a modified CA developed by Hainmuller 
et al. [33], which has recently also been used in empiri-
cal ethics [34]. This choice-based conjoint design iden-
tifies the average marginal component effect (AMCE), 
the marginal effect of changing one characteristic in a 
patient profile averaged over the joint distribution of all 
the remaining patient characteristics. The AMCE can be 
explained with an example: if we compare a randomly 
drawn patient with a positive biomarker to a randomly 
drawn patient with a negative biomarker, how much 
more likely is the patient with the positive biomarker to 
be given the new drug?
We decided to use this modified CA because it has sev-
eral strengths relevant for our survey: (1) It allows us to 
include a broad range of patient characteristic, in stead 
of pre-selecting two or three characterstics we believed 
would be most relevant. (2) It is able to capture mul-
tidimensional preferences, which typically are present 
in clinical decision making. (3) It can estimate causual 
effects of various patient characteristics at the same time, 
making more complex analysis of clinical decision mak-
ing possible. (4) It does not rely on modelling assump-
tions and complex statistical methods.
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We developed our experiment based on published 
recommendations [35, 36], with the modifications 
required by our specific type of CA. Selection of the 
attributes was based on both their ethical relevance 
for priority setting [2] and observational data from 
clinical practice [6] and resulted in seven patient 
characteristics relevant for treatment decisions in a 
metastatic cancer scenario. With input from clini-
cal experts we then gave each patient characteristics 
a set of realistic values. Table  1 presents the included 
patient characteristics and levels. In our design a total 
of 3 × 2 × 3 × 3 × 2 × 3 × 2 = 648 different patient pro-
files were possible. We did not judge any of the possi-
ble combinations to be illogical, although a patient with 
severe comorbidity and an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of 0 would 
perhaps have been clinically unusual (but not impos-
sible). The experiment was tested in a pilot with eight 
doctors. Based on this feedback we made some minor 
adaptations.
The questionnaire had three sections. The first sec-
tion was for the conjoint analysis. The second section 
asked a general question about background values 
shaping the priority setting for individual patients, and 
the third and final section asked questions about the 
respondents’ background. The survey is available in 
Additional file 1.
Distribution and analysis
The survey was programmed and distributed, and 
responses were collected by Ideas2evidence, a company 
specialising in survey development and administra-
tion. Confirmit, a web-based survey software was used. 
Respondents could access the questionnaire at any time 
during the data collection period, using a smartphone, 
tablet or computer. Responses were stored in the soft-
ware and exported for analysis after data collection 
ended.
A general invitation to participate in the survey, 
with an accompanying link to the questionnaire, was 
emailed to 1 029 potential participants in the beginning 
of March 2019 using email lists from three specialized 
medical associations and a network of gynaecologi-
cal oncologists in Norway. These were selected as they 
represent a large majority of doctors treating cancer 
patients in Norway and are familiar to biomarker-based 
diagnostics. A reminder was emailed 2  weeks later. 
Data collection ended after 5 weeks.
AMCE was estimated with a linear regression model, 
where allocation to treatment is the dependent out-
come variable and all the patient characteristics are 
explanatory variables. For each characteristic one level 
is designated as a baseline value. The statistical analy-
sis was conducted in R/RStudio version 3.6.1 and the 
R-package “cregg” [37]. Dataset and syntax are available 
in the supplementary section (see Additional file 3 and 
4).
A total of 115 participants completed our survey, giv-
ing a total of 690 observations in our sample. Charac-
teristics of the respondents are presented in Table  2. 
The majority of respondents are working in the field 
of oncology and at university hospitals. Only 21% have 
less than 5  years of experience working with cancer 
patients, and almost half of them treat more than 20 
patients in a regular week.
Ethical approval
The study was reported to and evaluated by the Nor-
wegian Centre for Research Data (reference number 
583480). We did not collect any patient information 
whatsoever. Accordingly, the study was exempt of the 
requirement of medical ethics approval as regulated by 
the Norwegian Health Research Act [38]. Attached in the 
email invitation sent to potential participants was a link 
to an informed consent form and information about data 
protection.
Table 1 Patient characteristics and accompanying levels 
included in the conjoint analysis
*Defined as a 50% probability of better effect than average
**These characteristics were given a more detailed description. This is available 
in the supplementary material
Patient characteristic Value
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Results
The AMCEs from our conjoint analysis are presented 
in Fig.  1 and show that there is a 25 percentage point 
(pp) increased probability that respondents would give 
the new drug to a patient with a positive biomarker, 
compared to a patient with a negative biomarker, when 
averaged on all other possible combinations of patient 
characteristics. We shall refer to these computed fre-
quencies as “probabilities” for allocation. Biomarker 
status produced the third largest effect of the patient 
characteristics in the experiment: a patient aged 87 years 
has a 47  pp reduced probability of being allocated the 
new treatment compared to a patient aged 63, and a 
patient with severe comorbidity has a 26  pp reduced 
probability of being allocated the new treatment com-
pared to a patient with no comorbidity. All these findings 
were statistically significant.
Other patient characteristics with a significant effect on 
the probability of being allocated the new treatment were 
patient age 75 years (21 pp reduced probability compared 
to age 63), ECOG performance status 1 and 2 (7 pp and 
19  pp reduced probability compared to ECOG perfor-
mance status 0) and moderate comorbidity (6 pp reduced 
probability compared to no comorbidity). Importantly, 
sex, smoking status and education level had no signifi-
cant impact on the probability of being allocated the new 
treatment.  An additional analysis of marginal means is 
available in Additional file 1.
In Fig.  2 we present answers to the question about 
background values and show that biomarker status 
was rated as “important” or “very important” for treat-
ment decisions by 83% of the respondents. None of the 
respondents expressed that biomarker status was unim-
portant. The characteristic considered as overall most 
important is performance status, where 88% of the 
respondents rated it as “important” or “very important” 
for their treatment decision. Comorbidity and patient age 
were rated as “important” or “very important” by 74% 
and 67%, respectively.
A large majority of the respondents considered 
patients’ sex (89%) and education levels (78%) as not 
important. The patients’ responsibility for their health 
was the characteristic with the most variation in ratings. 
26% rated it as “important” or “very important” for the 
treatment decision, while 27% rated it as “a bit impor-
tant” and 20% as “not important”.
Discussion
Our main findings are that in our sample a positive bio-
marker status significantly increases the probability of 
being allocated the new cancer treatment, while older 
age, a higher degree of comorbidity and reduced physical 
Table 2 Demographics of survey participants
*1 retired, 1 Ph.D. fellow, 1 junior, but in senior position


















University hospital 81 (70%)
Regional hospital 17 (15%)
Local hospital 17 (15%)
Experience working with cancer patients
< 5 years 24 (21%)
5–15 years 48 (42%)
> 15 years 43 (37%)
Number of patients treated in a regular week
< 5 9 (8%)
5–20 50 (43%)
> 20 56 (49%)
Fig. 1 The average marginal component of changing one individual 
patient characteristic, compared to its baseline characteristic. Lines 
represent 95% confidence intervals. A positive AMCE indicates a 
higher probability of being allocated the new drug, while a negative 
AMCE indicates a lower probability
Page 5 of 9Tranvåg et al. BMC Med Ethics           (2021) 22:55  
function significantly reduce this probability. Sex, educa-
tion and smoking status do not influence the probability. 
Many of these findings are in line with what is commonly 
seen as relevant ethical factors for treating patients une-
qually: A patient’s functional status and comorbidity are 
considered relevant because they are proxies, that could 
say something about the potential to benefit from treat-
ment. Sex and education are not considered relevant. The 
fact that biomarker status and age are seen as relevant is 
particularly interesting, as if and how they should be seen 
as ethically relevant in decision making is disputed.
We find that a positive biomarker status increases the 
probability of being allocated the new treatment, com-
pared to a negative status. Whether a biomarker can 
be seen as relevant depends on what the biomarker is a 
proxy for and how good a proxy it is. Importantly, a bio-
marker in itself is not inherently ethically relevant. In our 
survey the biomarker is a predictive marker, a proxy for 
health benefit. Health benefit, or the potential to benefit, 
has strong support in the normative literature and is also 
shown to be perceived as relevant by clinicians, policy-
makers and the public [39]. An example of a predictive 
biomarker is PD-L1 in lung cancer [40]. Other biomark-
ers can be both predictive and prognostic, like HER2 [11].
We find that old chronological age reduces the prob-
ability of being allocated the new treatment, compared 
to a younger age. This is an interesting finding, as the 
relevance of patient age in priority setting is heavily con-
tested [41–44]. Many endorse the view that age can be 
indirectly relevant if it correlates or informs some other 
factor that is seen as ethically relevant (e.g. risk of disease, 
or survival). This view is also endorsed in the official Nor-
wegian white paper on priority setting [45]. Accepted as 
indirectly relevant, chronological age is often interpreted 
as a proxy for biological age, which again may indicate 
something about the potential to benefit from a treat-
ment [46]. However, we find that age is the single most 
important factor in priority setting decisions, even when 
comorbidity and performance status also are included. 
This could be interpreted as age is given an independent 
and direct relevance, based on normative claims like the 
fair innings argument.
The fair innings argument argues that at some age, orig-
inally suggested at the age of 70, one can consider oneself 
to have had her or his fair share of life, and that any addi-
tional time added after that age should be considered a 
sort of bonus [41, 47, 48]. If one dies before the age of 
70 however, some injustice is being suffered because that 
person has not had the chance to live a reasonable length 
of life. The fair innings argument then requires efforts 
and priorities to be made to give as many as possible the 
chance to live until that age, while those who has passed 
that age, should be given less priority. Such reasoning 
is much more controversial [49] that the indirect use of 
age in priority setting and may be seen as ageism [50]. 
How our respondents reasoned about age in their prior-
ity setting decisions are difficult to assess. In our results 
there seem to be discrepancy between the important role 
given to age in our experiment and how important the 
respondents have replied when directly asked about the 
importance of age. One possible answer to this may that 
the hypothetical scenarios elicit other and perhaps more 
true answers from respondents on controversial issues 
like age and priority setting [28].
A common view is that treating equal patients une-
qually based on their age can be ethically acceptable if 
Fig. 2 The respondents’ answers to the question “How important are the following factors for your treatment decision about patients?”
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patient age indirectly is a proxy for other ethically rele-
vant factors (such as treatment benefit), and if this corre-
lation is strong. We argue that a similar approach is also 
true for biomarkers: treating equal patients unequally 
based on a predictive biomarker is only acceptable if the 
biomarker predicts treatment effect, and, importantly, 
if this prediction is of good quality. A similar argument 
would also be true for prognostic biomarkers. Such con-
cerns may explain why respondents in our survey attach 
only moderate importance to biomarker status, as they 
may have felt uncertain about the quality of the generic 
biomarker presented in the survey. Further work could 
investigate how doctors process and use information 
about biomarker status and patient age in their clinical 
reasoning.
Ian Majewski and René Bernards have proposed three 
key aspects of biomarker tests when considering its regu-
latory trajectory [51], and these are also useful for judg-
ing a biomarker’s quality in clinical decision making [16]. 
A biomarker test should have analytical validity, meaning 
that it must be reproducible, accurate and validated, so 
that it measures what it is supposed to measure and the 
measurements are consistent. If a biomarker test demon-
strates significant variations in its analytical validity, its 
claim to be an ethically relevant factor for decision mak-
ing would weaken.
A good biomarker should also be clinically valid, mean-
ing that it must provide clinically useful information rel-
evant for the decision at hand. A prediction of treatment 
response is clearly relevant. In our survey, we informed 
the respondents that a positive biomarker status gave “a 
50% probability of an effect better than the average”. This 
may be seen as too general a prediction, but this was 
deliberate. The survey was distributed to doctors with 
different specialties treating different types of cancer, so 
we wanted a generic experiment. The breadth in available 
biomarkers is large, and the average benefit from many 
new cancer drugs is modest [52, 53]. The current discus-
sion about surrogate endpoints in precision oncology 
[54] is also important for a biomarker’s clinical validity. If 
a biomarker predicts tumour shrinkage or a pathological 
complete response, it is not clear how this should inform 
a treatment decision without evidence of these surrogate 
markers also influencing survival [55] or quality of life 
[56].
A biomarker should also have clinical utility, that is, 
actually influence decision making. This depends both 
on the biomarker itself and the context in which it is 
used. A test that has good analytical and clinical valid-
ity, as discussed above, may inform clinical decisions 
in a legitimate and ethical way, but this is also context 
dependent. Are tests and drugs available to all patients? 
Does the health care system have guidelines or formal 
processes that guide biomarker use in clinical deci-
sions? How does tradition and organizational culture 
influence decisions? And do decision makers accept 
and trust biomarkers as part of their input into clinical 
decisions? This latter question is one that we explore in 
this article.
We believe our findings have three important impli-
cations. First, the results from our hypothetical stated 
choice experiment show that in our sample doctors 
seem to accept biomarker status as relevant for treat-
ment decisions, but it is not seen as the most important 
characteristic. This may illustrate valid concers about 
uncertainty. Precision medicine may have led to more 
precise diagnostics and targeted treatments, but para-
doxically, the evidence supporting it is, at present, often 
less precise [57]. This uncertainty about evidence in 
precision oncology also translates into clinical decision 
making [58].
Second, doctors have to balance the competing con-
cerns for equality with the best available treatment for 
individual patients, all with an increasing degree of 
uncertainty. How they reason and make decisions needs 
more research and attention as their ability to navigate 
in this ethically and clinically challenging landscape is 
of great importance: For patients with advanced can-
cer, access to potentially beneficial treatment can be 
a matter of life and death. In health care systems, the 
principle of equality is a matter of justice, solidarity and 
legitimacy [59, 60].
Third,  we wish to encourage a broader debate about 
individual biomarkers’ validity and utility. It is well-
known that e.g. PD-L1 as a predictive biomarker has 
significant shortcommings in its analytical and clini-
cal validity [61, 62], but it is still part of clinical prac-
tice and guidelines [63]. Seemingly technical decisions 
on tissue fixation, assay properties and thresholds for 
positive tests also raise important normative challenges 
[17]. Biomarkers should therefore not be automatically 
integrated and accepted in clinical decision making. A 
highly sophisticated biomarker will not automatically 
improve health, nor promote fair priority setting [64].
Using Majewski and Bernard’s framework to evalu-
ate individual biomarkers could be a step forward to 
guide a fair implementation of biomarkers and preci-
sion oncology: if a biomarker is analytically and clini-
cally valid, and provides clinical utility; it can be seen 
as an ethically relevant factor for providing treatment 
to some patients while denying it to others, even if they 
have the same disease. And importantly, to base treat-
ment decisions on a flawed and poor quality biomarker 
should be seen as unethical and in conflict with the 
principle of equal treatment.
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Strengths and limitations of the study
Given the momentum and strong attention to precision 
medicine, we believe our findings are timely and impor-
tant. The relevance of biomarker status and age in pri-
ority setting are disputed but seem to be perceived as 
relevant in our sample. To our knowledge, this is the first 
survey to include biomarker status in a priority setting 
scenario with expensive cancer drugs.
Conjoint analysis is a well-known method from other 
fields and has several advantages. A potential limitation 
for this method is its reliance on a random and uniform 
distribution of patient profiles used in the conjoint anal-
ysis [65]. The median age of incidence for all cancers in 
Norway is 69 years, making patients aged 87 less frequent 
than patients aged 75 and 63. However, although not uni-
formly distributed in real clinical practice, all our char-
acteristics and levels were within recommendations in 
clinical cancer guidelines in Norway, making all possible 
combinations realistic.
As this experiment was conducted in Norway, our 
results might not be transferable into other contexts 
with other frameworks for priority settings. However, 
limited clinical benefit and high costs of cancer medi-
cine is a global challenge [66, 67], which makes the cir-
cumstances in our experiment fairly applicable to many 
other settings. We acknowledge the importance of shared 
decision making and that an informed and autonomous 
patient should be part of the final treatment decision. In 
our hypothetical experiment we decided to exclude this 
as a factor in order to isolate and explore the opinions of 
the doctors.
Our estimated response rate of 11% may invite ques-
tions about the validity of our results, challenges well-
known for email surveys [68]. Low response rates in 
surveys among doctors is a recognized problem [69], but 
it is also argued that responding and non-responding 
doctors share many similar characteristics [70]. Never-
theless, the results from our sample should not be gener-
alized. Our convenience sampling strategy, low response 
rate and missing information about non-respondents 
limit the external validity of our findings. Therefore this 
should be seen as a first exploratory study to map the use 
of biomarker status alongside other patient characteris-
tics in priority setting decisions. We believe our results 
can serve as a useful base for discussion and generate 
hypotheses for further research.
Conclusion
In our sample biomarker status is perceived as relevant 
for priority setting decisions, alongside other more well-
known patient characteristics like age, physical function 
and comorbidity. Whether biomarkers should be used 
as a factor for stratifying patients and providing unequal 
treatment should depend on the proprerties of the bio-
marker: Biomarkers with sufficient analytical and clinical 
validity and clinical utility may be seen as an ethically rel-
evant factor for giving unequal treatment to patients with 
the same disease.
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